translation agency

BBC News
MedMira Rapid HIV Test Makes Steady Progress in OTC Market: 2nd Shipment of MiraCare(TM) Rapid HIV Test to Retail Pharmacies Completed

February 17, 2005
HALIFAX, Feb. 17 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has completed a second shipment of its Over-The-Counter (OTC) MiraCare(TM) Rapid HIV Test (MiraCare(TM)) against a standing order. Since MiraCare's(TM) introduction, the number of retail pharmacies selling the test has increased from 50 to over 300. This second shipment comes just three weeks following the launch of this product into Hong Kong and Macao, China announced on January 24, 2005. MiraCare(TM) is distributed to pharmacies in Hong Kong and Macao by Goodman Medical Supplies Ltd., a well-established medical supply distributor in this region, and is the first in MedMira's new line of products destined for OTC purchase.

"As with all new products, introductory sales volumes have not yet reached mass-market levels, but the consumer and retailer response to our OTC rapid HIV test has been tremendous", said Hermes Chan, president and chief operating officer of MedMira. "Feedback from the retail pharmacies has been very positive, and we are encouraged by the acceptance of the general public for a rapid OTC test for HIV." Chan continued, "Goodman's 40 years of marketing experience and strong pharmacy networks in these regions, together with our proven technology, is an invaluable combination".

MiraCare(TM) is sold as a complete test package with all components required for an individual to conduct the test quickly; with results showing in just three minutes.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro flow-though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com.

MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available.

MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

SOURCE MedMira Inc.



www.aegis.org